-
Featured
What We Have Learned About COVID-19: Part One
Since the initial outbreak of COVID-19, clinicians have treated hundreds of thousands of patients. At the same time, over 55,000 COVID-related research articles have been published (albeit of heterogeneous quality). There is now substantial consensus on optimal treatment of the critically ill patient with COVID-19.
-
COVID-19 Vaccine Candidates
The effort to produce and distribute a SARS-CoV-2 vaccine has made remarkable progress. Currently there are over 180 candidate vaccines against SARS-CoV-2 in development worldwide.
-
What Is a Superspreader Event?
The primary mode of transmission of SARS-Cov-2 is close contact between persons. Accordingly, there has been a heavy emphasis on effective non-pharmaceutical interventions. Breakdowns in physical distancing and gatherings have been associated with significant numbers of infections.
-
Expedited Publication in the Era of COVID-19
An unprecedented volume of academic literature has been produced since the start of the COVID-19 pandemic. Lessons may be learned from the expedited publication approach.
-
Cardiac Arrest and COVID-19
In-hospital cardiac arrest (IHCA) during the COVID-19 pandemic presents a unique set of resuscitation challenges such as exposure risk to clinical providers and obstacles to family communication. In this FLARE, we provide a brief review of IHCA in the pre-COVID-19 era and then discuss emerging evidence regarding IHCA during the COVID-19 pandemic.
FLARE contributors
-
Camille Petri, MD
Research Fellow, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital
Recent Article
Helmet Ventilation May Be Considered for Selected Patients with Mild COVID-19–Associated ARDS -
Charles Corey Hardin, MD, PhD
Physician, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School, Physician Investigator, Pulmonary, Mass General Research Institute
Recent Article
Commentary: Widely Reported Study of Therapeutic Anticoagulation for COVID-19 Has Serious Flaws
-
David M. Dudzinski, MD
Intensive Care Cardiologist, Massachusetts General Hospital, Director, Cardiac Intensive Care Unit, Associate Editor, Case Records of the MGH
Recent Article
International Perspectives: Optimizing Cardiac Critical Care During the COVID-19 Pandemic
-
Erica Seiguer Shenoy, MD, PhD
Associate Physician, Massachusetts General Hospital, Associate Chief of the Infection Control Unit, Massachusetts General Hospital
Recent Article
What Is a Superspreader Event?
-
Jason H. Maley, MD
Research Fellow in Medicine, Massachusetts General Hospital
Recent Article
Commentary: Widely Reported Study of Therapeutic Anticoagulation for COVID-19 Has Serious Flaws -
Laura N. Brenner, MD
Pulmonologist, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital
Recent Article
Effects of COVID-19 on Pregnant Women and Neonates -
Raghu Chivukula, MD, PhD
Physician-Scientist, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital
Recent Article
Identification of Novel Bronchiectasis Syndrome Has Implications for Other Respiratory Diseases
-
Tiara Calhoun, MD
Internal Medicine and Global Medicine Resident, Massachusetts General Hospital
Recent Article
Study of Interferon + Antivirals in COVID-19 Is First Published Randomized Trial with Positive Results -
Vladimir Vinarsky, MD
Instructor in Medicine, Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital
Recent Article
Neutralizing SARS-CoV-2-specific Antibodies and Virus-Specific T Cells Detected in People Recovering from COVID-19
Pulmonary and Critical Care Medicine
The Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital provides comprehensive care for the full range of respiratory conditions and diseases.Related Links
